Progress toward the development of Lassa vaccines

References

• Murphy HL, Ly H. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments. Virulence. 2021;12(1):2989–3014. PMID: 34747339. doi: 10.1080/21505594.2021.2000290
   PubMed Web of Science ®Google Scholar
• Murphy H, Ly H. Understanding immune responses to Lassa virus infection and to its Candidate vaccines. Vaccines. 2022;10(10):1668. PMID: 36298533. doi: 10.3390/vaccines10101668
   Web of Science ®Google Scholar
• Fathi A, Dahlke C, Addo MM. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum Vaccin Immunother. 2019;15(10):2269–2285. Epub 2019 Sep 5.PMID: 31368826. doi: 10.1080/21645515.2019.1649532
   PubMed Web of Science ®Google Scholar
• Sulis G, Peebles A, Basta NE. Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. Trop Med Int Health. 2023 Jun;28(6):420–431. Epub 2023 Apr 24.PMID: 37095630. doi: 10.1111/tmi.13876
   PubMed Web of Science ®Google Scholar
• Tschismarov R, Van Damme P, Germain C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. Lancet. 2023 Apr 15;401(10384): 1267–1276. Epub 2023 Mar 16.PMID: 36934733. doi: 10.1016/S0140-6736(23)00048-X.
   PubMed Web of Science ®Google Scholar
• Fischer RJ, Purushotham JN, van Doremalen N, et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines. 2021 Mar 2;6(1):32. PMID:33654106 10.1038/s41541-021-00291-x
   PubMed Web of Science ®Google Scholar
• Carrion RJ, Patterson JL, Johnson C, et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine. 2007 May 16;25(20):4093–4102. Epub 2007 Feb 27.PMID: 17360080. doi: 10.1016/j.vaccine.2007.02.038
   PubMed Web of Science ®Google Scholar
• Lukashevich IS, Carrion RJ, Salvato MS, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008 Sep 26;26(41):5246–5254. Epub 2008 Aug 8.PMID: 18692539. doi: 10.1016/j.vaccine.2008.07.057
   PubMed Web of Science ®Google Scholar
• Cai Y, Ye C, Cheng B, et al. A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene. MBio. 2020 Feb 25;11(1):e00039–20. PMID: 32098811. doi: 10.1128/mBio.00039-20
   PubMed Web of Science ®Google Scholar
• Ronk AJ, Lloyd NM, Zhang M, et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat Commun. 2023 Sep 12;14(1):5603. PMID: 37699929 10.1038/s41467-023-41376-6
   PubMed Web of Science ®Google Scholar
• Brisse M, Vrba SM, Kirk N, et al. Emerging concepts and technologies in vaccine development. Front Immunol. 2020 Sep 30;11:583077. PMID: 33101309 doi: 10.3389/fimmu.2020.583077
   PubMed Web of Science ®Google Scholar
• Vrba SM, Kirk NM, Brisse ME, et al. Development and applications of viral vectored vaccines to combat zoonotic and emerging public Health threats. Vaccines (Basel). 2020 Nov 13;8(4):680. PMID: 33202961. doi: 10.3390/vaccines8040680.
   PubMed Web of Science ®Google Scholar
• Dhanwani R, Zhou Y, Huang Q, et al. A novel live pichinde virus-based vaccine vector induces enhanced humoral and cellular immunity after a booster dose. J Virol. 2015 Dec 16;90(5):2551–60. PMID:26676795 10.1128/JVI.02705-15.PMID:
   PubMed Web of Science ®Google Scholar
• Lauterbach H, Schmidt S, Katchar K, et al. Development and characterization of a Novel non-Lytic cancer Immunotherapy using a recombinant arenavirus vector platform. Front Oncol. 2021 Oct 14;11:732166. PMID: 34722273 doi: 10.3389/fonc.2021.732166
   PubMed Web of Science ®Google Scholar
• Schmidt S, Mengistu M, Daffis S, et al. Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive HBV-specific CD8 T cell responses and high anti-HBs titers. J Infect Dis. 2023 Aug 21;jiad340. Online ahead of print.PMID: 37602681 doi: 10.1093/infdis/jiad340
   PubMedGoogle Scholar
• Boopathy AV, Sharma B, Nekkalapudi A, et al. Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys. NPJ Vaccines. 2023 Nov 10;8(1):175. PMID: 37945621 10.1038/s41541-023-00768-x
   PubMed Web of Science ®Google Scholar